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Proposal  for  a 
COUNCIL  DECISION 
---------
accepting,  on  behalf of  the  European  Economic  Community, 
theConvention on  the elaboration of  a  European  Pharmacopoeia 
(presented  by  the  Commission) ., . 
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EXPLANATORY  MEMORANDUM 
1.  Origin of  the  European  Pharmacopoeia 
The  Convention on  the elaboration of  a  European  Pharmacopoeia,  which  was 
signed on  4  September  1964,  entered  into  force  In  1974.  It  currently covers 
19  European  countries: 
the  12  Member  States of  the  European  Community; 
6  member  count~ies of  the  European  Free  Trade  Area  (EFTA); 
Cyprus. 
The  ex-USSR,  Poland  and  Hungary  have  recently  Indicated  their  interest  in 
the Convention. 
2.  Aims  of  the  European  Pharmacopoeia 
The  European  Pharmacopoeia  forms  part of  the general  framework  for  the 
harmonization of  national  laws  on  the manufacture,  circulation and 
distribution of  medicines  In  Europe. 
The  aim  of  the  progressive establishment  of  a  common  Pharmacopoeia  for  the 
European  countries concerned  is,  as stated  In  the  recitals to  the 
Convent ion,  to: 
"harmonize  specifications  for  medicinal  substances which,  in  their 
original  state or  in  the  form  of  pharmaceutical  preparations,  are of 
general  interest  and  importance  to  the  peoples of  Europe"; 
"hasten  the  drawing  up  of  specifications  for  the  growing  number  of  new 
medicinal  substances  appearing on  the maiket." - 3  -
The  harmonized  monographs  of  the  European  Pharmacopoeia  become  official 
technical  rules which  are  applicable  in  the countries of  the  Contracting 
Parties.  They  are chiefly  intended  for  the  pharmaceutical  industry  and 
the control  authorities as well  as,  to a  lesser  extent,  dispensing 
pharmacists. 
3.  FunCtioning of  the  European  Pharmacopoeia 
The  European  Pharmacopoeia  Commission  is  instructed  to prepare  and  to adopt 
technical  decisions on  the monographs.  It  consists of  eminent  scientists 
appointed  by  each  of  the Contracting Parties for  their  competence  and  elects 
a  Chairman  from  among  its members.  The  Public Health  Committee  of  the 
Counci I  of  Europe  administratively oversees  these activities and  in 
particular  lays  down  the date  for  implementation of  the monographs,  although 
it may  not  alter  any  of  their  technical  content. 
The  work  is prepared  by  a  number  of  groups of  experts  in  conjunction with 
the Secretariat of  the  Pharmacopoeia,  which  has  qualified scientific staff 
and  a  technical  laboratory.  The  Secretariat also  publishes  the successive 
editioris of  the  European  Pharmacopoeia  and  manages  and  distributes the 
reference substances  to which  it  refers. 
4.  Benefit  of  the  European  Pharmacopoeia  to  the  Community 
From  the outset,  harmonization of  the  quality  requirements  for  medicinal 
substances  and  preparations  has  been  an  objective of  both  the  European 
Community  and  the  European  Pharmacopoeia.  The  binding  nature of  the 
European  Pharmacopoeia  has  been  strengthened  by  Community  directives on  the 
testing of proprietary medicinal  products  for  human  use  and  veterinary 
medicinal  products,  which  include  several  references  to  the  Pharmacopoeia. - 4  -
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The  respective annexes  to. councl 1  Directive 75/318/EEc<1>,  as  amended,  and 
to CouncU  Dlrective.81/852/EEc<2>,  as  amended;  .similarly state that:  "The 
monographs  of·  the  European  Pharmacopoeia  shall  apply  to all  substances 
appearing  In  It".  ·This  Is therefore certainly an  area of  Community 
competence,  as  confirmed  at  a  latter  date  by  the  Council  during  the 
extension between  1989  and  1992  of  Community  pharmaceutical  regulations  to 
alI  industrially prepared medicinal  products  for  human  or  veterinary use. 
5.  The  need  for  the accession ofthe European  Community. 
As  this  is  an  area of  Community  competence,  it  is  necessary  to  regularize 
the situation by  enabling  the Community  to accede  to  the  Convention  on  the 
elaboration of  a  European  Pharmacopoeia  by  means  of  an  appropriate  Protocol. 
For  its part,  the Commission  regarded accession as an  important  aspect of· 
Its programme  for  the  free  circulation. of· medicinal  products and  for  th.is 
reason  included  in  its  "White  Paper  on  completing  the.  internal  mark.et". 
This matter  has  also been  regul~rly discussed since 1985  in  the  competent 
bodies of  the  European  Pharmacopoeia  with  the partlcipatian of  a  European 
Community  observer.  The  committees  of  government  experts set  up  to advise 
the Commission,  in  particular  the  Pharmaceutical  Committee,  the  Committee 
for  Propri~tary Medicinal  Products and  the Committee  for  Veterinary: 
Medicinal  Products,  have  helpe~ t6  consol~date the  discussions and 
consultat.lons with.  the  bodies of  the  European  Pharmacopoeia. 
6.  The  Protocol  enabling  the  Community  to accede 
By  Decision of  26  May  1987,  the Council  authorized  the  Commission  to conduct 
· negoHations,  within  the  framework  of the  Council  of  Europe,  to .enable  the 
EEC,  wl th  Its Member  .States,  to accede  to  the  Convent ion. on  the  e 1  aborat ion 
of a  European  Pharmacopoeia.  As  the  Initial  version .of  the  Convention  was 
open  to·  Individual· countries only,  the  negotiations  led  to  the .draftJng of 
(1)  OJ  L 147,  9.6.1975. 
(2)  OJ  L 317,  6.11.1981. - 5  -
an  additional  Protocol  to enable  the  EEC  to accede  to  it,  the  text of which 
was  approved  by  the Council  of  the  European  Communities  on  7  March  1988. 
The  Protocol  was  then  signed  by  the Contracting Parties  In  November  1989. 
The  Council  of  Europe  informed  the  Community  that,  with  the deposit of  he 
last  instruments of  ratification,  the Protocol  enabling  the Community  to 
become  a  Contracting Party  to  the Convention  on  the  European  Pharmacopoeia 
entered  Into  force  on  1  November  1992. · 
7.  Contents of  the  Protocol 
As  approved  by  the Counci I  on  7  March  1988,  the  Protocol  in  particular  lays 
down  the  decision-making  procedures  in  the  two  bodies  responsible  for  the 
functioning of  the  Eu_ropean  Pharmacopoeia  (Publ lc Health  Committee  and 
European  Pharmacopoeia  Commission).  After  coordination between  the  Member 
States of  the  Community,  the  European  Community,  represented  by  the 
Commission  of  the  European  Communities,  exercises  the  voting  rights to which 
the  Member  States'  delegations are currently entitled. 
However,  the  Community  does  not  vote on  the  technical  matters discussed  In 
the  European  Pharmacopoeia  Commission  In  order  to  respect  the scientific 
independence of  the delegates who  are personally appointed  for  their 
technical  competence.  The  Community  therefore displays  its confidence  in 
the scientific value of  the work  carried out  within  the context  of  the 
European  Pharmacopoeia.  It  would  therefore  I Ike  to rely  fully  on  the 
expertise of  the members  of  the  European  Pharmacopoeia  Commission. 
B.  The  proposal  for  a  Decision  Is  accompanied  by  the  text of  the  Convention 
on .the elaboration of  a  European  Pharmacopoeia,  which  was  signed  in  1964, 
and  the  Protocol  enabling  the  European  COmmunity  to accede  to  It,  which 
entered  Into  force  on  1  November  1992.  A financial  statement  on  accession 
is attached  to  the  proposal. 
The  Commission  would  ask  the Council  to adopt  the  proposal  for  a  Decision 
accepting,  on  behalf of  the  European  Economic  Community,  the Convention  on 
the elaboration of  a  European  Pharmacopoeia. ...,  6  -
PROPOSAL  FOR  A COUNCIL  DECISION 
accepting,  on  behalf of  the  European  Economic  Community, 
the Convention on  the elabororation of  a  European  Pharmacopoeia 
THE  COUNCIL  OF  THE  EUROPEAN  COMMUNITIES. 
Having  regard  to  the Treaty establishing  the  European  Economic  Community, 
and  In  particular Article  113  thereof, 
Having  regard  to  the. Commission's  proposal, 
Whereas  the Convention  on  the elaboration of  a  European  Pharmacopoeia,  which 
was  drawn  up  within  the  Counci I of  Europe,  aims  to  harmonize  specif·.ications 
~or medicinal  substances and  pharma~eutical  preparations  to enable  them  to 
circulate  in  Europe;  whereas  the monographs  of  the  European  Pharmacopoeia 
become  official  technical  rules applicable within  the  territories of  the 
countries which  are Contracting Parties to  the Convention; 
Whereas  such  measures  are  now  more  than  ever  necessary  for  the manufacture, 
circulation and  distribution of  medicinal  products  In  Europe  in  order  to 
facll itate trade betwee.n  the Community  and  .the  other  ContracHng Parties  to 
the  Convention; 
Whereas,  furthermore,  the Community  has  already,  in  Council 
Directive 75/318/EEC  of  20  May  1975  on  the  approximation of  the  laws  of  the 
Member  States relating to ana1ytical,  pharmacotoxological  and  clinical 
standards and  protocols  in  respect  of  the  testing of  medicinal  products<1>, 
as  last  amended  by  Directive 91/507/EEC  of  19  July  1991(2),  and  Council 
Directive 81/852/EEC  of  28  September  1981  on  the  approximation of  the  laws 
of  the  Member  States  relating  to analytical,  pharmacotoxological  and 
clinical  standards  and  protocols  in  respect  of  the  testing of  veterinary 
medicinal  products<3>,  as  last  amended  by  Directive 92/18/EEC  of 
(1)  OJ  L 147,  9.6.1975,  p.  1. 
(2)  OJ  L 270,  26.9.1991,  p,  32. 
(3)  OJ  L 317,  6.11.1981,  p.  16. - 7  -
20.  March  1992(4),  unilaterallY  recognized  the compulsory  nature of  the 
European  Pharmacopoeia  monographs  for  all  products covered  by  the 
abovement I  oned  DIrect I  ves; · 
HAS  DECIDED  AS  FOLLOWS: 
Sole article 
The  Convention on  the elaboration of  a  European  Pharmacopoeia  is  hereby 
accepted on  behalf of  the  European  Economic  Community. 
The  texts of  the Convention  and  the  Protocol enabling  the  European  Economic 
Community  to accede  to  i·t  are  attached  to this Decision. 
The  President of  the Council  is hereby  authorized  to notify acceptance  to 
the Counci I of  Europe,  the depositary of  the Convention  and  the  Protocol, 
and  to designate  the persons empowered  to s·lgn  the Agreement  for  the  purpose 
of  commIttIng  the  Comniun I ty  to  It. 
Done  at  Brussels, 
(4)  OJ  L  97,  14.4.1992,  p.  1. - 8  -
CONVENTION 
ON THE ELABORATION 
OF A EUROPEAN PHARMACOPOEIA - 9  -
CONVENTION  ON  THE  ELABORATION 
OF  A EUROPEAN  PHARMACOPOEIA 
The Governments of the Kingdom of Belgium, the French Republic, the Federal 
Republic of Germany, the Italian Republic,the Grand Duchy of Luxembourg, the King-
dom  of  the  Netherlands, the  Swiss  Confederation  and  the  United  Kingdom of Great 
Britain and Northern Ireland, 
Considering  that  the  Parties to the Brussels Treacy  of  17th March 1948, as 
amended on  23rd October  1954, resolved to strengthen the social ties  by which they 
are  united  and  to  make _every  -effort  in common,  both .by  direct  consultation and in 
specialised Agencies, to raise the standard of living of their peoples and promote the 
harmonious development of social services in their·respective countries; 
Considering  that the  social activities governed by the Brussels  Treacy  and 
carried  on,  until  1959,  under  the  auspices of  the Brussels Treaty Organisation  and 
the  Western  European  Union  are  now  conducted within the  framework  of the Council 
of Europe, in accordance with the decision taken on 21st October 1.959  by the Council 
of  Western  European  Union  and  with  Resolution (59)  23  adopted  on  16th November 
1959 by the Committee of  Ministers of the Council of Europe; 
Considering that the Swiss Confederation has participated since 6th May  1964 
in activities in the  field  of  public health carried on  under the aforesaid  Resolution; 
Considering  that  the  aim  of  the  Council  of  Europe  is  the  achievement of 
greater unity between its Members  in order to. pr~mote,  inter alia, economic and social 
progress by  the conclusion of  agreements and by common action in economic, social, 
cultural, scientific, legal and administrative matters; 
Considering that,  so far  as  possible, they- have endeavoured to promote pro-
gress  both  in the  social field  and  in the related field  of  public health and that they 
. have  undertaken the  harmonisation  of  their  national  laws  in  pursuance of the afore-
mentioned provisions; 
Considering that such measures are now  more  than ever necessary in  respect 
of  the  manufacture, circulation and distribution of  medicines in Europe; 
Convinced that  it  is desirable and  necessary to harmonise specifications for 
medicinal  substances  which,  in their original state or  in the form  of  pharmaceutical 
preparations, are of general interest and importance to the peoples of Europe; - 10  -
Convinced  of  the  need  co  hasten  the  drawing  up  of  specifications for the 
growing  number of  new  medicinal substances appearing on the market; 
Considering chat chis  aim can best be achieved by the progressive establish-
ment of a ·common pharmacopoeia for the European countries concerned, 
Have agreed as follows  : 
ARTICLE 1 
Elaboration  of a  European  Pharmacopoeia 
The. Contracting Parties undertake : 
(a) progressively co  elaborate a  Pharmacopoeia which shall be common to the 
countries concerned and which shall be entitled "European Pharmacopoeia"; 
(b) to take  the necessary measures  to ensure that the  monographs which will 
be  adopted  by  virtue  of  Articles  6  and  7  of  c.he  present Convention and  which will 
constitute  the  European  Pharmacopoeia shall  become  the  official  standards applic-
able within their respective  countries~ 
ARTICLE  2 
Organs concerned with the elaboration of the European Pharmacopoeia 
The elaboration of the European Pharmacopoeia shaH be undertaken by: 
(a) The  Public  Health Committee  whose  activities are carried  on  within the 
framework of the Council of Europe, in accordance with Resolution (59) 23 mentioned 
in  the  Preamble  to  the  present  Convention,  hereinafter referred  to  as· ''the Public 
Health Committee" ;  . 
(b) A  European  Pharmacopoeia Commission established  by  the  Public Health 
Committee for  this purpose, hereinafter referred to as "the Commission". 
ARTICLE 3 
Composition of the Public Health Committee 
For  the  purposes  of  the  present  Convention,  the  Public  Health  Committee 
shall  be  composed  of  national  delegations  appointed  by  the  Contracting Parties. - 11  -
ARTICLE 4 
Functions  of  the  Public Health Committee 
1.  The  Public  Health  Committee  shall  exercise  a  general  oversight  over the 
activities of  the Commission and  for this purpose the Commission shall submit a  r~ 
port on each of its sessions co the Public Health Committee. 
2.  All  decisions  taken  by  the  Commission,  other  than those of  a  tee hnical or 
procedural character,  shall be subject to the  approval of the Public Health Commie-
tee. If the  Public Health Committee does not  approve a  decision or apprm:es it only 
partially, the  Committee  shall refer it back to the Commission for  further considera-
tion. 
3.  The  Public  Health  Committee,  having  regard  to the  recommendations of the 
Commission under  Article 6 (d),  shall fix the time  limits within  which decisions of a 
technical  character  relating  to  the  European  Pharmacopoeia  shall  be  implemented 
within the territories of the Contracting Parties. 
ARTICLE 5 
Membership of the Commission 
1.  The Commission shall be  composed of  national delegations appointed by  l~-e 
Contracting  Parties.  Each  delegation shall consist  of  not  more  than three membt·;s 
chosen for  their competence in matters within the functions of the Commission. Each 
Contracting  Party  may  appoint  the  same  number  of  alternates  similarly  competen:. 
2.  The Commission shall draw  up  its own Rules of Procedure. 
3.  The  Commission  shall  elect a  Chairman  from  among  its  members  by  secret 
voce. The term of  office of the Chairman and  the conditions governing his re-election 
shall  be  laid  down  in the  Rules  of  Procedure  of  the  Commission, provided that the 
ter-m  of  office  of  the first  Chairman  shall  be  three  years.  While he holds office, the 
Chairman shall not  be  a  member of  any national delegation. 
ARTICLE 6 
Functions of  the Commission 
Subject to the provisions of  Article 4 of the present Convention, the functions 
of  the  Commission shall be  : 
(a) to  determine  the  general  principles applicable  to  the  elaboration  of  the 
European Pharmacopoeia; 
(b) to decide upon  methods of  analysis for that purpose; - 12  -
(c) to  arrange  for  the  preparation of and to adopt monographs to be included 
in the European Pharmacopoeia; and 
(d) to .recommend the fixing  of  the time  limits within which its decisions of a 
technical  character  relating  to the  European  Pharmacopoeia  shall  be implemented 
within the territories of the Contracting Parties. 
ARTICLE 7 
Decisions of the Commission 
1.  Each of  the national delegations  mentioned in Article 5 (1) shall be entitled 
to one vote. 
'  ' 
2.  On all technical matters, including the order in which the mo.nographs referred 
to in Article  6 are to be prepared, ·decisions of  the Commission shall be taken by a 
unanimous  vote  of  delegations casting a  vote and  a  majority  of  the delegations en-
titled to sit  on the Commission. 
3.  All other decisions of  the Commission shall be taken by a  two-thirds majority 
of the votes cast and a  majority of  the delegations entitled to sit on the Commission.. 
ARTICLE 8 
Seat and  meetings or the  Commission 
1.  The Commission shall hold its meetings at Strasbourg, the seat of the Coun-
cil of Europe. 
2.  It shall be convened by  its Chairm~n and  meet as often as necessary, but at 
least twice a  year. 
3.  It shall meet in private; the working languages shall be the ·official languages 
of  the Council of Europe.  ·  · 
4.  The  Public  Health Committee may appoint an  observ~r to attend  meetings of 
the Commission. 
ARTICLE 9 
Secretariat  or the  Commission 
The Commission shall have  a  Secretariat, the head and the technical staff of 
which  shall  be  appointed  by the  Secretary-General  of  the  Council  of Europe on the 
advice  of  the  Commission and  in conformity wfth the  Administrative  Regulations of - 13  -
the Council of  Europe staff. The other members of  the Secretariat shall be  ~ppointed 
by  the ·  Secreta:ry-General in consultation with the head of the Commission's Secret· 
anat. 
ARTICLE  10 
Finances 
1.  The expenses of the Secretariat of  the Commission and all other common ex· 
penses incurred in the execution of the present Convention shall be borne by the Con• 
tracting  Parties in  accordance  with the provisions of  paragraph  2  of  this  Article. 
2.  Pending the conclusion of  a  special arrangement agreed to by all Contracting 
Parties for this purpose, the financial administration of operations carried out under 
the present  Convention shall be dealt with in accordance with the provisions of the 
Partial  Agreement  Budget  in  the  social field  relating to the  activities covered by 
Resolution (59)  23 referred to in the Preamble to the present Convention. 
ARTICLE  11 
Entry into rorce 
1.  The present Convention shall be ratified or accepted by the Signatory Govern-
mencs.Instruments of ratification or acceptance shall be deposited with the Secretary-
General of .the Council of Europe. 
2.  The present  Convention shall enter into force  three months after the dace of 
deposit of the eighth instrument of ratification or acceptance. 
ARTICLE 12 
Accessions 
L  After the  date of the entry into force of  the  present Convention, the Commit-
tee of  Ministers of  the Council of Europe,  siccing  with its membership limited co the 
Representatives of the Contracting Parties, may invite, on  such conditions as it con· 
siders  appropriate,  any  other Member  State of  the Council co  accede to  the present . 
Convention. 
2.  After  the expiry of  six  years  from  the  said date, the Committee of Ministers 
may invite, on such conditions as it considers appropriate, European States not mem_. 
bers of  the Council of Europe to accede to the present Convention. 
3.  Accession shall be effected  by  depositing  with the Secretary-General of the 
Council of  Europe an instrument  of accession, which shall cake effect three months 
after the dace of its deposit. - 14  -
'<. 
Territorial Application 
1.  Any  Government  may,  at the time of  signature or when depositing its instru-
ment  of  ratification,  acceptance  or  ac<:ession,  specify the territory or territories to 
which the present Convention shall apply.  ·  . 
..  ' 
2.  Any  Government  may,  when depositing its instrument of ratification,''accept-
ance  or  atcession  or  at  any later date,  by  dec iaration addressed to the Secretary.;, 
General of  the Council of Europe,  extend the  present Convention to any other terri-
tory  or territories specified in the  declarati.on and  for  whose  international relations 
it is responsible or  on whose behalf it is authorised to give undertakings  • 
. '. 
3.  .  Any declaration made in pursuance of the preceding paragraph may, in respect 
of  any  territory  m~ntidned in  s'ltch  declaration,  be  withdrawn according to the  pro-
cedure  la~d down inArticle 14  of the present Convent.ion.  .  · 
ARTICLE 14 
Duration 
1.  The present Convention shall remain in f~rce indefinitely. 
2.  Any Contracting  Party  may,  so  fa~ as. it  isconcer~ed,· denounce the  pre~ent 
Convention  by  means  of  a  notificat.ion  addressed to  the Secretary-General  of 'the 
Coun<:il of EU:rope;  ·  · 
., 
3.  Such denunciation  shall take  effect  s1x  months after the date  of  receipt by. 
the Secretary-General of such notification. 
ARTICLE  15 
Notifications 
The  Secretary-General  of  the  Council  of  Europe  shall  notify  Contracting 
States of : 
(a) any signature; 
(b) the  deposit  of  any  instrume.nt  of  ratification,  acceptance or ac cess10n; 
(c;)  the date  of  entry into force  of  the  present Convention in accordance with 
Article 11, 
(d) any  declaration  received  1n  pursuance  of  the  prov1s10ns  of  Article 13; - 15  -
(e) any notification received in pursuance of che  provisions of  Article  14  and 
the date on which denunciation takes effect. 
ARTICLE 16 
Suppiementary Agreements 
Supplementary agreements  may  be  made  concerning the detailed implementa• 
cion of  the provisions of  the present Convention  • 
.  ARTICLE  17 
Provisional Application 
Pending the entry into force  of the present Convention in accordance with the 
provisions of  Article  11,  the Signatory Scates agree, in orderto avoid any delay in 
the implementation of  the present Convention, co. apply it provisionally from the date 
of signature, in conformity with their respective constitutional systems. 
In  witness  whereof  the undersigned,  being  duly  authorized thereto, 
have  signed the present  Convention. 
Done  at  Strasbourg,  this  22nd  day  of ·July  1964  ih  English  and 
French,  both  texts being  equally athoritative  in a  a  single  copy  which 
shall  remain  deposited  in  the  archives  of  the  Council  of  Europe.  The 
Sec~etary-General shall  send  certified copies  to  each  of  the  signatory 
and  acceding States. .  '  ·· .. 
.. 
·,  ' 
'  .. 
_  ...  :.  ~ .  . 
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PROTOCOL  TO  THE  CONVENTION  ON  THE  ELABORATION 
OF  A EUROPEAN  PHARMACOPOEIA 
Preamble 
The member StateS of  the Council of  Europe which are Parties to the Convention on the Elaboration 
of  a European Pharmacopoeia of  22 July 1964 drawn up within the Council of  Europe's Partial Agreement 
iri  lhe Social and Public Health Field, hereinafter called "the Convention", 
Having regard to the Convention and particularly to the provisions of Article 1 thereof; 
Considering that the European Economic Community has adopted rules particularly in the form of 
directives which apply to the matters covered by  the Convention and that it is  competent in this field; 
Considering therefore that,  for  the purpose of implementing Article  1 of the  Convention, it is 
necessary for the European Economic Community to be able to.  become a Party to the Convention; 
Considering that,  to that end, it is  nec~sary to  amend certain provisions of the Convention, 
Have agreed as follows: 
Article  1 
The term "national delegations" in Articles 3 and 5,  paragraph 1, of the Convention shall be  re-
placed by  the word  "delegations". 
Article 2 · 
The following text shall  replace Article 5, paragraph 3, of the Convention: 
"3.  The Commission shall elect a Chairman from among its members by secret ballot, by a two-thirds 
majority of the votes of the delegations. The term of  office of the Chairman and the conditions governing 
his  re-election shall be laid down in the Rules ofProcedure of the Commission. While he holds office, 
the Chairman shall not be a member of any delegation." 
-Article 3 
The following  text shall  replace Article 7 of the Convention: 
"1. .  Each of the national delegations shall be entitled to one vote. 
2.  On all technical matters, including the order in which the monographs referred to in Article 6 are 
to be prepared, decisions of the Commission shall be taken by a unanimous vote of national delegations 
casting votes and a majority of the national delegations entitled  to  sit on the Commission. 
3.  All other decisions of the Commission shall be taken by a three-quarters majority of the votes cast. 
For these decisions, from the time of entry into force of the Convention in  r~.spect of the European Econ-
omic Community, the latter's delegation shall vote in place of its member States' delegations. It shall have 
a number of votes equal to  the number of its  member States' delegations. 
However, should a Contracting Party alone possess the required majority, the Contracting Parties 
undertake to renegotiate the voting modalities no sooner than five years after the entry into force of the 
Protocol, at the request of one of them addressed to the Secretary General of the Council of Europe." 
.  ~ 
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Articlc4 
The following text shall be in.serred in Article 10 of  tlle Convention. as paragraph 3: 
..  3.  The conditions of  any financial pattlcipalion by the European Economic Community shall be deter-
mined by agreement between the Contracting Parties.-
Article 5 
I .  A  new paragraph .3  shall be insc:ttcd in Article 12 of the Convention. worded as follows: 
- ..  3.  The European. Economic Community may accede to the present Convention..•• 
2.  .  The former paragraph 3 of  Article 12 of  the Convention shall be renumbered as pan\gtaph 4 of 
the same .Article.. 
Article 6. 
A  new pamgraph 4  shall be insc:ncd in, Article 13  · ot the,  Convc:ntion.,  worded as follows: 
..  4.  Paragraphs 1. 2 and 3 above shall apply mraaris m.uran.dis to lhc European Economic Community  ... 
Article 7 
L  This Protocol shall be open for signatUre by the member States of  the Council of Europe having 
signed or acceded to the Convention which may eJCPress their consent to be boUDd by: 
a.· signature without reserwtion as to .nttification. acceptanec or approval ;· or 
b. signature subject tO  ratification. aa:cpamcc; or approval. followed by ratification, acceptance or 
approvaL 
2.  No member State of  tho Council of  Europe shall sign wi~out  reservation as to ratification, accept-
ance or approval; or deposit an insrrurnent or  ratification, acceptance or approval, unless it is already or 
becomes simultaneously· Party to the Convention_ ·  ·  ·· 
3.  Any State not a member of the Council of Europe which has acceded to  the Convention may also 
acc:cdc to this Protocol. 
4_  Instruments of  ratification. acceptance. approval or accession shall be deposited. with the Secretary 
General of the Council of Europe. 
. Article 8  · 
This Protocol shall enter into force on the first day of  the month folloWing the expiration of  a period 
of  one month after the date on which all Parties to the Convention have expressed th-:ir cotiSent to be 
bound by the Protocol in accordance with the proVisions of Article 7. 
Article 9 
The Secretary Oeneral of the Council of Europe _shall notify the member States of  the Council. any 
other Contracting State to  the Convention .and the European Economic Community of: 
a..  any sigaattire ; 
b_, the deposit of  any instrument of ratification. acceptance. approval or accession; 
c.  any date of entry into  force of this Protocol in accordance with Artide 8 ~ 
d.  any other aa, notification or communication relating to this ProtocoL 
In  witness  whereof  the  undersigned,  being  duly  authorized thereto,  have 
signed this Protocol. 
Done  at Strasbourg,  the 16th  day of  November  1989,  in  English  and 
in  French,  both  texts bPino  equally authentic,  in ·a  single  copy  which 
shall be deposited  in  the archives  ~f the  Council  of  Eu~ope.  The  Secretary 
General  of the  Council  of  Europe  shall transmit  certified copies  to  each 
Member  State of the  Council  of  Europe,  to  any  other Contractinq State  tQ 
the  Convention  and  to the  European  Economic  Community_  -- 19  -
FINANCIAL  STATEMENT 
P R 0  P 0  S A L  F 0  R  A  C 0  U N C  I  L  D E C  I  S  I  0  N 
ON  ACCESSION  TO  THE 
E U R 0  P E A N  P H A R M A C 0  P 0  E  I  A . - 20  -
SECTION  1:  FINANCIAL  IMPLICATIONS 
1. Title of oPeration 
Accession  to  the  European  Pharmacopoeia  Convention  (Counci I  of  Europe) 
2.  Budget  headings  Involved 
B  5~301  Phafmacopoeia 
[Reference  financial  statements  previously  produced  by  the Commission: 
SEC(86)2010  -
COM(87)697  -
(pp.  46.47) 
3.  Legal  basis 
Recommendation  for  a  Counci I  Decision on 
negotiations with  a  view  to accession  to  the 
Pharmacopoeia 
Extension of  the  pharmaceutical  directive~ to 
medical  products  not  yet  covered. 
(vaccines,  blood,  radiopharmaceuticals)] 
Article  113  6f  the  EEC  Treaty 
Commission  Directive 91/507/EEC  of  19  July  1991  amending  the  Annex  to 
Counci I  Directive  75/318/EEC  on  the  approximation of  the  laws  of  the 
Member  States  r~lating to analytical,  pharmacot6xicological ·and  clinical 
standards  and  protocols  in  respect  of  the  testing of  medicinal  product 
(OJ  L 270,  26.9.1991). 
Commission  Directive 92/18/EEC  of  20  March  1992  amending  the  Annex  to 
Counci I  Directive 81/852/EEC  on  the  approximation of  the  laws  of  the 
Member  States relating  to analytical,  pharmacotoxicological  and  clinical 
standards  and  protocols  in  respect of  the  testing 6f  veterinary medicinal 
products  (OJ  L 97,  14.4.1992). - 21  -
4.  Qescrlotlon of oPeration and  groynds  for  accession 
The  Convention on  the elaboration of  a  European  Pharmacopoeia,  which  was 
signed  in  1964  within  the Counci I  of  Europe,  entered  into force  In  1974.  It 
currently applies  in  19  European  countries,  including  the  12  Community 
Member  States. 
The  European  Pharmacopoeia  forms  part  of  the  framework  for  the  harmonization 
of  national  measures  relating to  the manufacture  and  quality control  of 
medicinal  products  in  Europe.  The  harmonized  monographs  of  the  European 
Phamacopoela  become  official  requirements  applicable within  the  territories 
of  the Contracting Parties. 
As  this  Is  an  area  in  which  responsibility  rests solely with  the Community 
·following  the adoption of  Council  Directives 75/318/EEC  and  81/352/EEC,  it 
is necessary  to regularize  the situation by  enabling  the  Community  to accede 
to  the Convention on  the elaboration of  a  European  Pharmacopoeia  by  means  of 
an  appropriate Protocol.  This objective  is  included  in  the  "White  Paper  on 
completing  the  internal  market". 
The  Protocol,  which  was  approved  by  the Counci I  on  7  March  1988,  has,  on 
1  November  1992,  now  been  ratified by  alI  of  the Contracting Parties.  The 
proposal  for  a  Council  Decision  is  therefore  intended  to enable  the  Counci I, 
on  behalf  of  the  Community,  to accept  the Convention  and  the  Protocol  to  it. 
Duration:  permanent  from  the date of  accession,  planned  for  1993. 
Target  population:  Community  citizens,  more  than  2  000  pharmaceutical  firms 
and  more  than  100  000  pharmacists. 
5.  Classification of expenditure 
5.1  Compulsory.expenditure 
5.2  Differentiated appropriations. - 22  -
·  6.  TYPe  of expendIture 
Annual  subsidy  towards  co-financing of  the  European  Pharmacopoeia.  The 
Pharmacopoeia  budget  is adopted  by  the  Committee  of  Ministers of  the  Counci I 
of  Europe.  The  purpose of  co~financing  is  to support  the  action  to be  taken 
on  a  priority basis  to  promote  the  free  movement  of  medicinal  products 
within  the Community  and  the  European  Economic  Area  (EEA)  such  as: 
the  faster  drawing  up  of  monographs  for  substances of  Co~munity benefit; 
the making  of  reference standards available  to  industry; 
collaborative  tests between  national  laboratories  for  the  control  of 
medicinal  products; 
biological  standardization  (vaccines,  blood  derivatives,  etc.). 
The  normal  budget  for  the  European  Pharmacopoeia  total led  approximately. 
ECU  4  400  000  (FF  30  641  000)  in  1992,  funded  from  the  contributions  paid  by 
the  19  countries which  are  Contracting Parties  to  the  Convention  in 
accordance  with  the  conventional  cost-sharing  formula  of  the  Counci 1 of 
Europe  (88.5%  to  be  borne  by  the  Community  Member  States).  To  this  has  been 
added  a  special  supplementary  budget  of  about  ECU  450  000  for  biol6~ical 
standardization,  including  ECU  300  000  funded  by  the  Community  on  the  basis 
of  a  special  contract  between  the  two  institutions. - 23  -
7.  Financial  Impact  of  the subsidY 
(a)  For  1993,  a  contribution of  ECU  300  000  for  the continuation of  the 
current  biological  standardization programme  is  included  under  item 
B 5-300.  ~he Act  of Accession  should normally enter  into  force 
around  the middle or  towaros.the end  of  1993. 
In  the meantime,  the  contribution of  ECU  300  000  under  the current 
framework  contract  for  biological  standardization signed on 
22  August  1991  wi  I I  make  it possible  to ensure  a  certain amount  of 
·continuity  in'cooperation  between  the  two  institutions  in  this 
sector  unti I  the  end  of  1993,  given  the uncertainty as  to  the exact 
date of  accession.  From  1994,  it  wi  I I  be  replaced  by  appropriations 
under  the  new  heading  B 5-301. 
(b)  From  1994,  the  Community's  overal I  subsidy  to  the  European 
Pharmacopoeia  under  the  new  budget  heading  B 5-301  wi  I I  amount  to 
ECU  750  000  and  is  intended  to cover  the  following  activities: 
- ECU  300  000  for  the  third biological  standardization  programme; 
- ECU  300  000  for  tests  in  cooperation with  the  national 
laboratories  for  the control  of  medicinal  products  and  to allow  the 
European  Pharmacopoeia  laboratory  to support  the  new  European 
Medicines Agency; 
- ECU  150  000  to  speed  up  the  adoption of  monographs  and  methods  of 
analysis  for  medicinal  products of  Community  benefit  and  for  new 
categories of  such  products covered  by  Community  legisiation,  e.g. 
homeopathy. 
(c)  After  1994,  the  annual  subsidy  to  the  European  Pharmacopoeia  wi  11 
follow  the  average  rate of  increase of  3%  of  expenditure.  The 
invariable costs wi  I I  not  need  to be  increased  in  1994. (d) 
B 
B 
* 
** 
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Indicative schedule of  commitment  appropriations 
1992  1993  1994  1995  1997'and 
successive  years 
5-300 *  300  000  300  000  - - -
5-301· **  p·.m.  p.m.  '  750  000  772  500  . 795  000  (+  3% 
. .  ..  per  annum) 
Current  framework  contract  signed  in  July  1991,  prior  to accession. 
After  the  Counci I  Decision,  planned  for  the  second  half  of  1993,  to 
accede  to  the Convent ion.  . 
8.  Anti-fraud measures . 
The  financial  control  of  the Counci I  O·f  Europe,  which  operates along  the 
same  1 ines as  the  financial  control  of  the Commission,  wi  I I  see  to  it  that 
proper  procedures  are .fo I lowed  in  respect  of  expenditure.  The  Commission 
·~  -,  . 
departments  wi  1.1  check  and  approve  the  subsidies  taking  account  of  the 
Counci I  Decision accepting  the Convention  and  the  principles of  economy  and 
of  sound.~inancial  and  overal I  management.  The· checks  wi  I I  in  particular 
cover  the  following: 
the. preparatory,wo.rki~g documents;  . 
the monographs  adopted  by  the  European  Pharmacopoeia  Commission; 
the official  publication of  the  monographs  by  the  Counci I  of  Europe; 
the  ~aking of  the official  reference preparations available  to  firms  and 
control  laboratories. 
The  Counci I  of  Europe  wi  I I  send  the  Commission  of  the  European  Communities 
ful I  annual  reports on  the use of  the  resources,  including  Justification 
concerning  the execution of  work. - 25  - ,,,. 
9.  Qost-effectlveness analYsis 
9.1 
9.1 .1 
(a) 
ObJectives  and  coherence  with  financial  programming 
Specific objectives: 
To  relaunch  and  speed  up  the  process of  adopting  compulsory 
monographs  for  the Quality of  conventional  medicinal  principals  from 
various sources  (generic medicinal  products). 
(b)  To  increase  the  number  of monographs  from  currently  600  (adopted 
since  1975)  to  1  000  by  1995  and  1  500  by  the  year  2000  so as  to 
faci I itate  intra-Community  trade  and  trade with  the  EFTA. countries· 
and  the developing  countries which  sti I I  apply  the  standards of  the 
French  and  British Pharmacopoeias. 
(c)  To  faci I itate  the  drawing  up  of  abridged marketing  authorization 
files containing  references  to  the  European  Pharmacopoeia. 
(d)  To  produce  European  reference standards  for  vaccines  and  biological 
products. 
9.1 .2  These  activities are  provided  for  in  the  finan~ial  programming  of 
DG  Ill. 
9.1.3  More  general  objective:  to  complete  the  internal  market  within  the 
pharmaceutical  sector.  Actions  included  in  the  White  Paper  in  1985. " 
- 26  .:.. 
9.2  Grounds  for  the operation 
The  European  Pharmacopoeia  (Counci 1 of  Europe,  Strasbourg)  has.  laboratories 
,:  . 
and  a  highly qualified  technical  secretariat with  a  staff of  about  40.  It· 
arr~nge~ ~earlY 75  meetings of  groups  of experts a  year,  with  its operating 
costs  1  imlted  to.expendlture on  administration,  the  laboratories and 
interpreting. 
The  Council  of  Europe  works  in  two  official  languages  (English  and  French) 
and  does  not  normally  reimburse  travel  expenses  to government  experts called 
to meetings.  Its apparent  oper~ting costs  ar~ therefore  r~l~fively  low 
compared  with  the  actual ·expenditure  to be  borne  by  the Contracting Parties 
to  the  Co~ventlcin. · 
The  alternative would  be  to ask  the Member.States  to withdraw  from  the, 
~harmacopoeia Convention  and  to draw  up  a  Community  Pharmacopoeia.  This 
·would Mcessi tate the  creation of  a  laboratory  Infrastructure and  the 
holding of  a  large  number  of  meetings  of  experts  at  Community  level  and 
would  entail  much  more  expenditure  than  within  the  Counci I  of  Europe 
.  (working  languages,  travel  expenses  of  experts). 
9.3  Monitoring  and  evaluation of  the operation 
9.3.1  Accession  to  the  Pharmacopoeia: 
Adoption  and  review,  three  times  a  year,  of  new  monographs  to be  published 
in  the  European  Pharmacopoeia,  in  accordance  with  priorities and  a  timetable 
to  be  agreed  in  consultation with  the  Community.  Following  accession,  the. 
Commission  will  intervene on  behalf of  the Member  States as  regards  policy 
decisions on  harmonization  by  the  Pharmacopoeia  and  determination of  the 
priority obJectives. - 27  -
The  production of  European  reference standards  to be  made  available  to  the 
European  pharmaceutical  Industry  and  of monographs  to be  published  in  the 
European  Pharmacopoeia. 
9.3.2  Performance  Indicators selected: 
Annual  activity reports,  summary  records of  the  European  Pharmacopoeia 
Commission,  official  publications of  the  European  Pharmacopoeia. 
Individual  notifications of results by  th~ Council  of  Europe  to  the 
Commission  of  the  European  Communities. 
9.3.3  Uain  factors of  uncertainty: 
The  abi I ity  to continue  the work  in  accordance  with  programmes  laid  down  by 
the  Counci I  of  Europe  in  conJunction with  the Community.  The  need  to 
mobilize  a  number  of  government  and  university experts whose  participation 
is  voluntary.  This uncertainty would  also exist  If  the work  were  done  by 
the  Community  Itself. 
10.  Administrative expenditure  for  the COqmlsslon  (part A of the budget) 
10.1  Staff 
.. 
Cooperation with  the  European  Pharmacopoeia  will  mean  increasing  the  number: 
of  permanent  staff  (under  the  St~ff Regulations)  in  Unit  II 1/C/3 
(Pharmaceuticals),  namely: 
- 1  ·A  (with  ph'armaceutlcal  qualifications), 
- 1  c ..  .. 
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It  wi  I I  be  necessary  to ensure  the appropriate coordination between  the  work 
of  a  number  of  working  parties of  experts of  the  Pharmacopoeia  and  the 
bodies  to which  the  Community  gives priority,  in  particular  the  Committee 
for  Proprietary Medicinal  Products  and  the Committee  for  Veterinary 
Medicinal  Products. 
10.2  Meetings 
The  Commission  wi  I I  have  to coordinate  the  position of  the Member  States of 
the  Community  for  each  of  the  three sessions of  the  European  Pharmacopoeia 
Commission  currently  held  and,  where  necessary,  before certain crucial 
meetings of  groups of  experts of  the  Pharmacopoeia. 
This  wi  I I  involve  additional  expenditure on  about  six  meetings  a  year  with· 
the  Member  States at  an  estimated cost  of  ECU  69  000.  These  wi  I 1 be 
meetings of  institutional  ~ommittees and  their  working  parties:  the 
Committee  for  Proprietary Medicinal  Products  and  the  Committee  for 
,, 
Veterinary Medicinal  Products  (item A 02510). 
''t  . .  ;~: t. 
10.3  Missions 
Provision  wi  I I  have  to  be  made  for  about  12 missions  a  year  to  the  steering 
bodies  and  to  various groups of experts of  the  Pharmacopoeia  which  generally 
meet  in  Strasbourg,  the  seat of  the  Counci I of  Europe.  These  expenses  are 
est  im~ted at  ab,out  ,ECU  5  000  per  annum. ISSN 0254-1475 
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